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INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is gener-
ally defined as a disease state characterized by the obstruc-
tion of airflow, which is not fully reversible (1). The major
risk factor for the development of fixed obstruction of airflow
in patients with COPD is cigarette smoking. The adverse
effect of smoking on the rate of decline in FEV1 have been
well documented in many cross-sectional and longitudinal
studies in normal populations. For example, Fletcher and
colleagues found that the average rate of decline of FEV1 was
0.03 L/yr among non-smokers, and that decline was twice
as fast among smokers (2). Broadly comparative figures for
rate of decline in FEV1 have been reported from several other
longitudinal studies (3-5).
Currently, the major hypothesis for the pathogenesis of
emphysema, which is a major component of the morbidity
and mortality of COPD, is the protease-antiprotease hypothe-
sis (6, 7). This hypothesis states that an imbalance between
the levels of degradative enzymes and their respective inhi-
bitors damages the connective tissue matrix components of
the lung. Among various proteases that have long been pro-
posed to damage connective tissue components in lung
parenchyma, there is now increasing evidence that matrix
metalloproteinases (MMPs) play a role in the pathogenesis
of COPD. In patients with emphysema, MMP-1 (collage-
nase) and MMP-9 (gelatinase B) was increased in bronchoalve-
olar lavage fluid (8). In addition, it increased the activities of
MMP-2 and MMP-9 in the lung parenchyma of patients
with emphysema (9). The interest in MMPs has been fur-
ther heightened by the demonstration in mice that emphy-
sema induced by chronic exposure to cigarettes is prevented
by deletion of the gene encoding MMP-12 (macrophage
metalloelastase) (10). The question remains how cigarette
smoking brings about the obstruction of airflow in COPD.
Increased expression of MMPs or an imbalance between
MMPs and their specific inhibitors, the tissue inhibitors of
metalloproteinase (TIMPs), may play a role in the generation
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Lung Matrix Metalloproteinase-9 Correlates with Cigarette Smoking
and Obstruction of Airflow
Cigarette smoking is the most important risk factor for obstruction of airflow in
chronic obstructive pulmonary disease (COPD). Matrix metalloproteinases (MMPs)
or an imbalance between MMPs and their inhibitors, the tissue inhibitors of MMP
(TIMPs), is considered to play a role in the pathogenesis of COPD. We investigat-
ed whether the MMPs expression or the imbalance between MMPs and TIMP-1 is
associated with the amount of cigarette smoking and the FEV1 value, in the lung
parenchyma of 26 subjects (6 non-smokers and 20 cigarette smokers). First, we
performed zymographic analysis to identify the profile of the MMPs, which revealed
gelatinolytic bands mainly equivalent to MMP-9 in the smokers. We then mea-
sured, using enzyme immunoassay, the concentrations of MMP-9 and its inhibitor,
TIMP-1. Correlation analysis revealed that both the MMP-9 concentrations and
the molar ratios of MMP-9 to TIMP-1 (MMP-9/TIMP-1) were correlated with the
amount of cigarette smoking. Furthermore, MMP-9 concentrations were inversely
correlated with FEV1. In conclusion, this study shows that MMP-9 expression in
human lung parenchyma is associated with cigarette smoking and also with the
obstruction of airflow, suggesting that MMP-9 may play a role in the pathogenesis
of the cigarette smoke-induced obstruction of airflow known as the characteristic
of COPD.
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of cigarette smoke-induced obstruction of airflow. However,
there is still no direct evidence of this results, although some
recent reports have revealed that there is an increased expres-
sion of MMP-9 by alveolar macrophages in cigarette smok-
ers compared to non-smokers (11, 12). 
Therefore, we hypothesized that the smoke from cigarette
would induce MMPs expression or an imbalance between
MMPs and TIMPs in lung parenchyma, and that it would be
associated with the degree of obstruction in airflow. To test
the hypothesis, we evaluated whether the amount of cigarette
smoking and FEV1 (% predicted) value, an indicator of air-
flow obstruction, are correlated with the MMPs expression or
the imbalance between the MMPs and TIMP-1 in human
lung parenchyma. 
MATERIALS AND METHODS
Subjects and Specimens
In a total of 26 subjects (6 non-smokers and 20 cigarette
smokers), specimens were obtained from lungs resected for
the treatment of malignancy or for the evaluation of solitary
pulmonary nodule. Immediately after resection, lung speci-
mens were collected at locations as far as possible from the
pathologic lesion. Subjects were excluded if the specimens
examined had microscopic evidence of ongoing infection or
malignant cellular infiltration. The study was approved by
Human Ethics Committee of Hallym University Sacred Heart
Hospital, and all subjects gave written informed consent.
Determination of the Amount of Cigarette Smoking
The definition of cigarette smoking was determined as
follows. Current smokers were defined as those who had
smoked at least 100 cigarettes in their lifetime and either
still have smoked or had quit smoking within the preced-
ing year. Among current cigarette smokers, the amount of
cigarette smoking was calculated as pack-year basis (PYs),
using a detailed questionnaire derived from a similar study
(13). If subjects had smoked at least 100 cigarettes in their
lifetime but had quit smoking more than one year earlier,
then they were classified as former smokers in terms of smok-
ing status and excluded from this study. Subjects who had
smoked less than 100 cigarettes including those who had
never smoked, were considered “never to have smoked” and
their exposure to environmental tobacco smoke was estimat-
ed by determining the following the number of people liv-
ing in the household who smoked at home, the number of
cigarettes smoked at the home each day, and the number of
hours the subjects spent daily outside the home in a place
where people were smoking. If these subjects suffered less
than 2 hr of passive smoking in a day, they were classified as
non-smokers.
Protein Extraction from Lung Specimens
For analysis of gelatinolytic activities and enzyme immuno-
assay for MMP-9 and TIMP-1, pieces of lung samples weigh-
ing between 0.5 and 1.5 g were kept in air-tight plastic bot-
tles at -80℃ until tissue extraction. After removal of small
vessels and bronchi under the microscope, the specimens,
which weighed 0.5 g each, were minced into small pieces
and homogenized with ULTRA-TURRAX T25 (Janke &
Kunkel GmbH & Company, KG, IKA Laboratory Technol-
ogy, Staufen, Germany) in an ice bath after the addition of
neutral salt extraction buffer (150 mM NaCl, 50 mM NaF,
10  g/mL of aprotinin, 10  g/mL of leupeptin, 1 mM Na3Vo4,
1 mM PMSF, 10 mM CaCl2, 2M KCl, and 50 mM Tris-HCl,
pH 7.5; 0.5 g tissue/2 mL buffer) (14). After incubation of
1 hr at 4℃, homogenates were centrifuged at 7.5×104 g
for 1 hr at 4℃. The supernatants were dialyzed against matrix
metalloproteinase buffer (5 mM CaCl2, 10 mM ZnCl2, 200
mM NaCl, and 50 mM Tris-HCl, pH 7.5) for 24 hr at 4℃.
Protein concentration of the samples was analyzed by a spec-
trophotometer (DU 640; Beckman, Fullerton, CA, U.S.A.)
according to the Bradford protein analysis method, and adjust-
ed equally to levels of 1.0 mg/mL (total protein concentra-
tion) for each sample. The samples were stored at -80℃until
analysis.
Gelatin Zymography
MMPs present in lung tissue protein extracts were detected
by their capacity to degrade gelatin according to a method
previously described (15). Briefly, protein extracts obtained
from lung tissue specimens were subjected to electrophoresis
on 12% polyacrylamide gels containing 1 mg/mL of gelatin,
in the presence of sodium dodecyl sulfate (SDS-PAGE) under
non-reducing conditions. After electrophoresis, gels were
washed twice in 1% Triton X-100 (vol/vol) for 1 hr, rinsed
briefly, and incubated at 37℃ for 24 hr in buffer containing
10 mM CaCl2, 5  M ZnCl2, pH 7.8 in Tris-HCl. After incu-
bation, the gels were stained with Coomassie Brilliant Blue
R250 and then destained in a solution of 10% acetic acid with
30% methanol. Zones of enzymatic activity were indicated by
negative staining, with areas of proteolysis appearing as clear
bands against a blue background. Molecular weight of the
gelatinolytic bands was estimated relative to size markers.
Measurement of MMP-9 and TIMP-1 by ELISA
The MMP-9 and TIMP-1 concentrations in protein extracts
were measured by enzyme-linked-immunosorbent assay
(ELISA) (MMP-9 & TIMP-1: R&D Systems Inc., MN,
U.S.A.). MMP-9 ELISA measured total MMP-9 released
(pro and active MMP protein together with that complexed
to TIMP-1+2). TIMP-1 ELISA measured both bound and
free TIMP-1.Lung MMP-9 Correlates with Cigarette Smoking and FEV1 823
Statistical Analysis
Results are expressed as medians and ranges. Statistical
analysis was performed using  2 test and Mann-Whitney U
test to assess differences between the two groups. Spear-
man’s rank correlation was calculated to assess correlation.
RESULTS
Characteristics of Subjects
Pathologic diagnoses of 26 subjects were lung cancer (22
subjects), tuberculous granuloma (3 subjects), and chondroid
hamartoma (1 subject). The study subjects were grouped as
non-smokers and cigarette smokers as follows;
Non-smokers: The six subjects (4 lung cancer, 2 tubercu-
lous granuloma) with no history of cigarette smoking ranged
from 31 to 67 yr of age (median: 62.5 yr). All six subjects
were females. The FEV1/FVC ratios (%) in the subjects ranged
from 73 to 87%, with a median value of 82.5%. The FEV1
(% predicted) values ranged from 89 to 118%, with a median
value of 105.5%.
Cigarette smokers: The 20 subjects (18 lung cancer, 1 tuber-
culous granuloma, 1 chondroid hamartoma) with current
smoking history ranged from 27 to 78 yr of age (median: 58
yr), with 19 males and one female. Cigarette smoking history
ranged from 3 to 104 pack-years (median: 40 pack-years). The
FEV1/FVC ratios (%) in the subjects ranged from 54 to 84%,
with a median value of 73.5%. The FEV1(% predicted) values
ranged from 45 to 118%, with a median value of 85.5%.
The comparison of the two groups is shown in Table 1.
Age distribution was similar between two groups, but gen-
der distribution was different (p<0.001). FVC (% predict-
ed) values were similar between the two groups. However,
FEV1 (% predicted) value and FEV1/FVC were significantly
lower among the cigarette smokers than the non-smokers
(p<0.005 and p<0.03, respectively), suggesting the presence
of obstruction of airflow in cigarette smokers.
Characterization of MMPs in Protein Extracts by
Zymography
To identify the profile of MMPs in the lung tissue proteins
of 26 subjects, we first performed zymographic analysis of
the protein extracts. It revealed the presence of a major gelati-
nase species having molecular weights of 92-kDa and 82-kDa,
which are equivalent to pro- and active- forms of MMP-9
molecules in the cigarette smokers (Fig. 1B). For the non-
smokers, gelatinolytic bands were rarely observed (Fig. 1A). 
Comparison of MMP-9 and TIMP-1 between Non-
smokers and Cigarette Smokers
According to the zymographic analysis, we selected MMP-
9 as one of the most probable candidate enzyme, and then
measured the concentrations of MMP-9 and one of its inhi-
bitor, TIMP-1. The concentrations of MMP-9 were higher
in protein extracts of the cigarette smokers (median: 51.45,
*Results are expressed as median, with ranges in parentheses. 
� p value
by 
2 test for sex variable. For other variables, by Mann-Whitney U test.
NS, not significant; PYs, pack-years; FEV1, forced expiratory volume in
one second; FVC, forced vital capacity.
Characteristics p value
� Non-smokers Cigarette  Smokers
(n=6) (n=20)
Age (yr) 62.5 (31-67) 58 (27-78) NS
Sex, male : female 0:6 19:1 <0.001
Cigarette Smoking (PYs) 0 40 (3-104) <0.001
Spirometry
FEV1 (% predicted) 105.5 (89-118) 85.5 (45-118) <0.005
FVC (% predicted) 93.5 (80-106) 88.0 (54-110) NS
FEV1/FVC (%) 82.5 (73-87) 73.5 (54-84) <0.03
Table 1. Characteristics of the subjects*
Fig. 1. The profile of matrix metalloproteinases (MMPs) in lung tis-
sues by gelatin zymography. The figure shows multiple clear
bands in the cigarette smokers (C1-C20) (B), as compared with
the non-smokers (N1-N6), in which gelatinolytic bands are rarely
seen (A). Arrows indicate the positions of pro- and active- forms
of MMP-9 (92 and 82 kDa, respectively). Zones of enzymatic
activity are indicated by negative staining, with areas of proteoly-
sis appearing as clear bands against a blue background. *Posi-
tive control.
N1     N2     N3     N4   N5          N6      *       *
Size marker Size marker
224 kDa
96 kDa
51.5 kDa
A
C12  C13  C14  C15  C16  C17 C18 C19  C20
Size marker
224 kDa
96 kDa
51.5 kDa
C
C1  C2        C3  C4  C5 C6  C7C8 C9   C10 C11
Size marker Size marker
224 kDa
96 kDa
51.5 kDa
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range: 7.20 to 129.90 ng/mL) than the non-smokers (medi-
an: 14.70, range: 1.40 to 16.10 ng/mL) (p<0.001, Mann-
Whitney U test) (Fig. 2A).
The concentrations of TIMP-1 were higher in the cigarette
smokers (median: 11.15, range: 7.90 to 20.80 ng/mL) than
the non-smokers (media: 8.10, range: 5.40 to 14.40 ng/mL)
(p<0.045, Mann-Whitney U test) (Fig. 2B).
The molar ratio of MMP-9 to TIMP-1 (MMP-9/TIMP-
1) was higher in the cigarette smokers (median: 1.26, range:
0.24 to 2.36) than the non-smokers (median: 0.49, range:
0.01 to 1.35) (p<0.021, Mann-Whitney U test) (Fig. 2C).
Correlation of MMP-9 and MMP-9/TIMP-1 with
Cigarette Smoking
Among the 26 subjects, there was a positive correlation of
MMP-9 concentrations with the amount of cigarette smok-
ing (rs=0.577, p<0.002) (Fig. 3A). In addition, there was
also a positive correlation of the molar ratio of MMP-9 to
TIMP-1 with the amount of cigarette smoking (rs=0.430,
p<0.028) (Fig. 3B).
Correlation of MMP-9 and MMP-9/TIMP-1 with FEV1
Among the 26 subjects, there was an inverse correlation
of MMP-9 concentrations with the FEV1 (% predicted) val-
ues (rs=-0.553, p<0.003) (Fig. 4A). However, correlation
analysis of the molar ratio of MMP-9 to TIMP-1 with the
FEV1 (% predicted) values failed to show statistical signifi-
cance, although it tended to increase according to the sever-
ity of obstruction of airflow (rs=-0.356, p<0.074) (Fig. 4B).
Fig. 2. Concentrations of MMP-9 (A), TIMP-1 (B), and the molar
ratios of MMP-9 to TIMP-1 (MMP-9/TIMP-1) (C) in lung tissues
from the non-smokers and cigarette smokers. Horizontal lines
indicate medians. Statistical analysis by Mann-Whitney U test.
M
M
P
-
9
 
(
n
g
/
m
L
)
120.0
90.0
60.0
30.0
Non-smokers Smokers
p=0.001
A
M
M
P
-
9
/
T
I
M
P
-
1
 
m
o
l
a
r
 
r
a
t
i
o 2.0
1.5
1.0
0.5
Non-smokers Smokers
p=0.021
C
T
I
M
P
-
1
 
(
n
g
/
m
L
)
20.0
15.0
10.0
5.0
Non-smokers Smokers
p=0.045
BLung MMP-9 Correlates with Cigarette Smoking and FEV1 825
DISCUSSION
This study showed that in human lung parenchyma, MMP-
9 expression and the molar ratio of MMP-9 to TIMP-1 were
increased in cigarette smokers when compared with non-
smokers, and that both the MMP-9 expression and the molar
ratio of MMP-9 to TIMP-1 were correlated with the amount
of cigarette smoking. Furthermore, this study also revealed
inverse correlation of the concentration of MMP-9 in lung
parenchyma with the FEV1 (% predicted) value, an index of
the obstruction of airflow of cigarette smokers.
Obviously, cigarette smoking is the most important cause
of obstruction of airflow, which is the characteristic of COPD.
In humans, however, there has been no direct evidence con-
firming that MMPs expression is increased according to the
amount of cigarette smoking or that their expression is asso-
ciated with the degree of obstruction of airflow observed
among cigarette smokers. To our knowledge, this is the first
study showing that MMP-9 expression in human lung
parenchyma is associated with the amount of cigarette smok-
Fig. 3. Correlation of MMP-9 (A), and the molar ratio of MMP-9 to TIMP-1 (MMP-9/TIMP-1) (B) with the amount of cigarette smoking in lung
tissues from the non-smokers and cigarette smokers. PYs, pack-years. Statistical analysis by Spearman’s rank correlation analysis.
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ing, and also with the obstruction of airflow in cigarette
smokers.
Previous studies have shown that MMP-9 is consistently
increased in emphysema patients or cigarette smokers. Fin-
lay and coworkers demonstrated that the secretion of MMP-
1 and MMP-9 and the expression of MMP-1 and MMP-9
mRNA were increased in the alveolar macrophages from
emphysema patients (8). Ohnishi and coworkers demonstrat-
ed that the elastolytic activities of MMP-2 and MMP-9 were
increased from emphysematous lung tissues when compared
with nonemphysematous lung tissues (9). Betsuyaku and
coworkers demonstrated that in bronchoalveolar lavage fluid
from 65 community-based elderly volunteers, the levels of
MMP-9 and MMP-8 were significantly higher in current
smokers with emphysema than in those without emphysema
(16). However, none of the above human studies analyzed
data in terms of the amount of cigarette smoking; instead
they merely considered the presence or the absence of emphy-
sematous change. Recently, Lim and coworkers demonstrat-
ed that alveolar macrophages obtained from bronchoalveo-
lar lavage fluid in current healthy smokers released greater
amount of MMP-9 and TIMP-1 compared with non-smok-
ers (11). In addition, Russell and coworkers studied the pro-
duction and the activities of macrophage-derived MMP-9
and TIMP-1 from alveolar macrophages from smokers with
COPD, healthy smokers and non-smokers (12). Their study
revealed that alveolar macrophages from smokers with COPD
released the greatest amounts of MMP-9, followed by healthy
smokers, and with MMP-9 expression from non-smokers
being the smallest. There is also a report that MMP-9 was
increased in serums from cigarette smokers when compared
with those from non-smokers (17). Therefore, we consider
that our results are well in agreement to the previously pub-
lished experimental data.
There exists a study that failed to verify increased expres-
sion of MMP-9 of lung parenchyma from patients with
emphysema (18). They examined the lung parenchyma of
23 patients with emphysema and of 8 normal control sam-
ples for the expression of MMP-1, MMP-9, and MMP-12
and reported that MMP-1 mRNA, protein, and activities
were present in the lung parenchyma of patients with emphy-
sema but not in the lungs of the controls. However, they did
not investigate further for the expression of MMP-9 protein
and its activities because they observed that MMP-9 mRNA
was expressed throughout the study subjects, irrespective of
the presence or absence of emphysema. In addition, they
did not analyze the data from the aspect of cigarette smok-
ing status or its amount.
Our study showed that MMP-9 expression and the molar
ratio of MMP-9 to TIMP-1 were increased among cigarette
smokers when compared with non-smokers, and that both
the MMP-9 expression and the molar ratio of MMP-9 to
TIMP-1 were correlated with the amount of cigarette smok-
ing. There exists a study showing similar results, in which
alveolar macrophages from cigarette smokers released greater
amounts of both MMP-9 and TIMP-1 than do alveolar macro-
phages from non-smokers, with a trend toward a higher
molar ratio of MMP-9 to TIMP-1 (11). However, in anoth-
er study that evaluated an imbalance between MMP-9 and
TIMP-1 in induced sputum of chronic bronchitic subjects
compared with controls, MMP-9 and TIMP-1 concentra-
tions were greater in sputum of patients with chronic bron-
chitis than in control subjects but the molar ratio of MMP-
9 to TIMP-1 was lower in chronic bronchitics than in con-
trol subjects (19). The difference might be explained from
that induced sputum is mainly obtained from large airways
and are unlikely to reflect pathophysiologic changes of lung
parenchyma. The major site of the chronic airflow limita-
tion in COPD are the small airways and lung parenchyma.
Therefore, we suggest that our study presents a more close
explanation for cigarette smoke-induced obstruction in air-
flow, which is characteristic of COPD.
Several studies have shown that cigarette smoking causes
an inflammatory process in central airways (20, 21), periph-
eral airways (22-24), and lung parenchyma (25). Cigarette
smoking leads to the accumulation of various inflammatory
cells including macrophages and neutrophils that are well
known to produce MMP-9. MMP-9 expression of these
inflammatory cells may increase in response to various inflam-
matory cytokines and oxidative stress caused by cigarette
smoking. It has previously been shown that an increase in
oxidant stress may increase MMP-9 activation (26, 27).
MMP-9 release from alveolar macrophages can be stimulat-
ed by lipopolysaccharide, interleukin-1 , and tumor necro-
sis factor- (11, 12, 28). These findings suggest that proin-
flammatory stimuli induced by cigarette smoking might
regulate MMP-9 activity in the COPD airways.
In conclusion, this study shows that MMP-9 expression
in human lung parenchyma is associated with cigarette
smoking and also with the obstruction of airflow. Further
study should follow to investigate the role of MMP-9 in the
pathogenesis of cigarette smoke induced airflow obstruc-
tion, which is the characteristic of COPD.
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